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Introduction
Enzyme replacement therapy (ERT) with Myozyme® has
significantly improved the prospect for patients with clas-
sic infantile Pompe disease. Yet, about 50% of patients still
do not survive ventilator-free beyond 2.5 years. In the pre-
sent study we compared the safety and efficacy of treat-
ment with 40 mg/kg/week to that of 20 mg/kg/ every
other week (eow) in 10 infantile patients to determine if a
higher/more frequent dose would improve outcomes. All
patients were treated for at least one year and received the
same dose throughout the study.
Results
Our outcome parameters included survival, ventilator
free survival, left ventricular mass index, motor outcome,
and infusion associated reactions. A total of six patients
received 20 mg/kg/eow, and four patients received
40 mg/kg/week. The median treatment duration was
3.5 years and 1.6 years, respectively. The median age at
the start of therapy was 1.5 months for the 20 mg/kg
group and 3.1 months for the 40 mg/kg group. During
the treatment period, 3 of the 10 patients became respira-
tory insufficient. They all belonged to the 20 mg/kg
group, and two of the three were CRIM negative. Four of
six patients in the 20 mg/kg group learned to walk, but
two later lost this ability after becoming ventilator depen-
dent. In contrast, all patients from the 40 mg/kg dose
group learned to walk and maintained the ability to walk,
even though their baseline motor functioning was gener-
ally worse. The decrease in left ventricular mass index
and the number of infusion associated reactions was
comparable in both groups.
Conclusion
The preliminary data of our study show that treatment
with Myozyme at a higher dose of 40 mg/kg/week is
generally well tolerated and leads to improved ventila-
tor-free survival and motor outcomes than treatment
with 20 mg/kg/eow.
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